35 Biotechnology & immunology
New Luminometer Designed to Accelerate and Simplify Mycoplasma Testing Announced
Lonza has further strengthened its extensive mycoplasma detection portfolio with the addition of the Lucetta™ 2 Luminometer, a single-tube system designed to simplify and accelerate mycoplasma detection in cell cultures. Pharmaceutical, biotechnology and academic researchers can now rely on this compact, portable and easy-to-use instrument to run Lonza’s MycoAlert™ Mycoplasma Detection Assays and obtain highly reliable results within just 20 minutes.
Mycoplasma contamination is one of the most common challenges facing cell-culture laboratories, and it can have a profound impact on cell integrity. However, some of the most widely used mycoplasma detection methods have been associated with time and quality inefficiencies. For example, the agar-and-broth procedure, although highly accurate, takes at least four weeks to complete, while the polymerase chain reaction method requires several hours with an increased likelihood for false positives and negatives.
“The expansion of our portfolio with the new Lucetta™ 2 Luminometer establishes Lonza as the leading provider of fast, simple and accurate mycoplasma detection solutions,” said Dr Claudia Schwartz, Product Manager for Cell Analysis at Lonza. “This small, lightweight instrument can be readily and directly integrated into standard cell-culture workflows without causing any interruptions. It offers highly sensitive and linear measurements of active mycoplasma enzymes in a fraction of the time needed for other techniques and with minimal effort. What’s more, the Lucetta™ 2 Luminometer comes at an affordable price, making it suitable for laboratories of all sizes.”
Lonza’s Lucetta™ 2 Luminometer provides a wealth of features and benefits, including: high data-storage capacity for up to 2,000 single sample readings; compatibility with a variety of test tubes, from regular 1.5 or 2 ml microcentrifuge tubes to 5 ml polystyrene tubes; intuitive software that guides users through the MycoAlert™ Mycoplasma Detection Assay routine without requiring any prior training; easy transfer of results to a Microsoft Exce® spreadsheet for long-term storage using the Lucetta™ Connect software platform; capability to run additional luminescence-based assays, such as Adenosine TriPhosphate-based cell proliferation or cytotoxicity assays and luciferase reporter gene assays.
48664pr@reply-direct.com
New Aspergillus Monoclonal Antibody
Aspergillus is a genus of aerobic fungi found widespread in the environment including air, water and food (think bread mould). They are harmless to those with healthy immune systems but can infect patients undergoing transplantation or chemotherapy and lead to disseminated disease (aspergillosis). If not controlled, fungal cells can infect major organs including lungs, heart and kidneys. Aspergillus fumigatus is the most frequently identified pathogen.
ViroStat has released a new Rabbit Monoclonal Antibody to Aspergillus species. This new antibody recognises numerous Aspergillus species and is reactive with all strains of Aspergillus fumigatus tested. It functions well in IFA, IHC and self-pairs in ELISA. Potential applications include rapid antigen detection systems such as ELISA and lateral flow immunoassay.
This new antibody joins a unique collection of existing Rabbit Monoclonal Antibodies to Candida albicans, Strep A, Strep B, Strep pneumoniae and Legionella from ViroStat. Download data sheets for these antibodies now.
More information online:
ilmt.co/PL/pvjv 47969pr@reply-direct.com
Experimental Cell Lines for CAR T Therapies
Amsbio has added new experimental cell lines to its CAR T cell research range.
Recent FDA approval of CAR T cells for treatment of leukemia and lymphoma has resulted in rapid growth in research on the therapeutic uses of such cells. The new Amsbio experimental cell lines provide you with the power to screen antibodies and ligands against your target, enhancing your search for new CAR T therapies.
A therapeutic Chimeric Antigen Receptor (CAR) is a transmembrane protein designed with an extracellular domain based on an antibody single-chain variable fragment (scFv) and intracellular signalling domains derived from the TCR g chain, along with other costimulatory
receptors. The scFv provides a specific binding domain that recognises target proteins on cancer cells. A patient’s own T cells are isolated and activated, then transfected with a gene expressing the CAR. This reprograms the T cells to identify and attack tumour cells expressing the target protein, creating personalised immune cells designed to specifically target the patient’s cancer.
New stable CHO recombinant cell lines are available from Amsbio for constitutively expressing full length human CD123, PSMA and ICOSL. Each stable clonal cell line was selected for different levels of expression to mimic different stages of cancer target cells with various CD123, PSMA or ICOSL expression levels.
Amsbio strives to provide tools at the cutting edge of cancer research and produce a growing list of experimental cell lines, recombinant proteins and screening services to advance the search for new CAR T cell therapies.
48788pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
